Kazia Therapeutics Limited (NASDAQ:KZIA – Get Free Report) was the recipient of a large decrease in short interest in February. As of February 15th, there was short interest totalling 90,500 shares, a decrease of 90.2% from the January 31st total of 921,900 shares. Based on an average trading volume of 1,770,000 shares, the short-interest ratio is presently 0.1 days. Approximately 3.1% of the company’s stock are sold short.
Kazia Therapeutics Trading Up 1.4 %
Shares of KZIA stock traded up $0.01 during trading hours on Friday, hitting $0.85. The stock had a trading volume of 48,270 shares, compared to its average volume of 2,885,768. Kazia Therapeutics has a one year low of $0.78 and a one year high of $15.80. The stock’s 50-day moving average price is $1.58 and its two-hundred day moving average price is $3.43.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Kazia Therapeutics stock. MAI Capital Management purchased a new stake in Kazia Therapeutics Limited (NASDAQ:KZIA – Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,363,894 shares of the company’s stock, valued at approximately $586,000. MAI Capital Management owned 51.66% of Kazia Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 30.89% of the company’s stock.
Wall Street Analyst Weigh In
View Our Latest Analysis on KZIA
About Kazia Therapeutics
Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.
Further Reading
- Five stocks we like better than Kazia Therapeutics
- Where Do I Find 52-Week Highs and Lows?
- Autodesk Designs Value for Investors: Uptrend Set to Continue
- How Can Investors Benefit From After-Hours Trading
- Anheuser-Busch Stock Rallies—Is the King of Beers Back?
- Most active stocks: Dollar volume vs share volume
- MarketBeat Week in Review – 02/24 – 02/28
Receive News & Ratings for Kazia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kazia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
